bottom line overweight rate ia reflect view
iqv combin data technolog research asset
enabl acceler sale growth continu expand total
address market believ fourth quarter beat
guidanc midpoint call acceler organ growth rate
support thesi
acceler growth rate resum rd report
fourth quarter organ growth nearli ahead
expect driven technolog analyt solut
segment solut rd also beat expect
along good book-to-bil result solid backlog growth
quarter give us confid outlook manag guid
organ growth acceler exclud
coronaviru headwind segment improv
limit acceler achiev last year company-wid
expect year none acceler
compani data secur llc estim reuter
adj acquisit integr relat expens restructur relat charg
stock-bas comp one time impact
adjust acquisit integr relat expens restructur relat
charg stock-bas comp one time impact
growth invest continu weigh near term margin
trajectori increment cost reduct program help
margin came expect quarter major
bucket omx saw less improv forecast
manag note continu make growth invest
margin accret long term may drive short term
pressur offset continu headwind manag
second round cost reduct program name
expect take cost top first
round hit run rate earlier expect
start benefit bottom line run rate
full cost takeout wrap
take account variou factor moder
margin trajectori slightli next two year
model updat updat estim
note herein increas
target price base
compani data secur llc estim reuter
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
price target
valuat ebitda estim arriv valuat
assum trade in-lin info servic group multipl roll forward
risk includ disrupt merger integr cancel delay reduc spend
due pharma econom weak pipelin repriorit compound failur rise interest
rate sale privat equiti sponsor
brought togeth power data softwar consult former im busi
abil run outsourc clinic trail quintil growth still feel effect slower
quintil book restructur integr engag busi expect re-acceler
iqvia largest contract research organ largest data provid pharma compani
